Exelixis

Exelixis shares are trading higher after the company recently reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628. On Thursday, Citigroup raised its price target from $45 to $56.